By Shaoyu Chang, MD, MPH, Senior Research Analyst, LSN
Corporate venture capital (CVC) funds are playing an increasingly important role in the early stage ecosystem and now are participating in one out of every five VC deals in the US. Almost all major pharmaceutical companies have now established CVC funds; meanwhile giants from other industries are exploring the life sciences horizon through their CVC arms.
Moderated by Donnie Mcgrath, VP of Business Development, Bristol Myers Squibb, this panel will feature:
- Mark Powers, CFO, Integrium
- Martin Heidecker, Director and Investment Manager, Boehringer Ingelheim Venture Fund
- Ann DeWitt, Senior Director, Sanofi-Genzyme BioVentures
- Ed Hu, Chief Financial Officer & Chief Investment Officer, Wuxi Venture Partners
What technologies are on CVC managers’ dreamlist? What are their key motivators and strategies? How should entrepreneurs start a dialogue with them? Experts from five prominent CVC funds will get together on the Corporate Venture Capital panel at RESI and speak their minds on these questions. You may have read our tips on partnering with CVC funds; RESI Boston will be a unique opportunity to meet them face-to-face.
Next Phase Newsletter 
Leave a comment